MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)

被引：0

作者：

Gupta, Shilpa

Ballman, Karla V.

Galsky, Matt D.

Morris, Michael J.

Chen, Ronald C.

Chan, Timothy A.

Dercle, Laurent

Wen, Yujia

Sridhar, Srikala S.

Yen, Aihua Edward

Grivas, Petros

Tan, Alan

Baghaie, Shiva

Rosenberg, Jonathan E.

机构：

[1] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA

[2] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA

[3] Tisch Canc Inst, New York, NY USA

[4] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, New York, NY USA

[5] Univ Kansas, Kansas City, KS USA

[6] Mem Sloan Kettering Canc Ctr, New York, NY USA

[7] Columbia Univ, New York Presbyterian Hosp, Dept Radiol, Med Ctr, New York, NY USA

[8] Univ Chicago, Chicago, IL USA

[9] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada

[10] Baylor Coll Med, Houston, TX USA

[11] Univ Washington, Seattle, WA USA

[12] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[13] Premier Onc Hem Assoc, Chicago, IL USA

[14] Alliance Clin Trials Oncol, Chicago, IL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

基金：

美国国家卫生研究院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4607

引用

页数：1

共 50 条

[21] A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy
Ciardiello, F.
Bang, Y-J.
Bendell, J.
Cervantes, A.
Brachmann, R.
Zhang, K.
Raponi, M.
Farin, H.
Shen, L.
ANNALS OF ONCOLOGY, 2018, 29 : 265 - 265
[22] Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial
Wu, Lingying
Li, Ning
Wang, Jing
Li, Qingshui
Wang, Danbo
Tang, Junying
Zhang, Cuiying
Zhang, Guonan
Hao, Min
Yao, Desheng
Duan, Wei
Gao, Qinglei
Wang, Li
Zhang, Youzhong
An, Ruifang
Yin, Rutie
Zhou, Qi
Yang, Hongying
Zhu, Jianqing
Jiang, Kui
Wu, Qiang
Zhao, Weidong
Huang, Yi
Xia, Bairong
Yang, Xinfeng
Li, Bo
GYNECOLOGIC ONCOLOGY, 2024, 190 : S74 - S75
[23] A multicentre, international, randomised, open-label phase 3 trial of avelumab plus best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100)
Powles, T.
Grivas, P.
Aragon-Ching, J. B.
Faroun, Y.
Kessler, E. R.
Tomita, Y.
Chakrabarti, D.
Laliberte, R. J.
Shnaidman, M.
Petrylak, D.
ANNALS OF ONCOLOGY, 2016, 27
[24] First-line Maintenance Therapy in adult Patients with locally advanced or metastatic Urothelial Carcinoma who are progression-free after platinum-based Chemotherapy
Rexer, Heidrun
Gschwend, Jurgen
Merseburger, Axel S.
AKTUELLE UROLOGIE, 2024, 55 (04) : 297 - 298
[25] Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial
Oh, D-Y.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, M. J.
Park, Oh
Hochhauser, D.
Arnold, D.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, E. M.
McGuinness, D.
Cui, K. Y.
Schlienger, K.
Locker, G. Y.
Kindler, H. L.
ANNALS OF ONCOLOGY, 2019, 30
[26] Phase III LEAP-011 trial: First-line pembrolizumab with lenvatinib in patients with advanced urothelial carcinoma ineligible to receive platinum-based chemotherapy
Loriot, Y.
Balar, A.
de Wit, R.
Garcia, J. A.
Grivas, P.
Matsubara, N.
Frenkl, T. L.
Sbar, E.
Jia, X. C.
Fouad, T.
Siefker-Radtke, A. O.
ANNALS OF ONCOLOGY, 2019, 30
[27] Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.
Kindler, Hedy L.
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Mercade Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke C.
Tortora, Giampaolo
Alguel, Hana
O'Reilly, Eileen Mary
McGuinness, David
Cui, Karen
Schlienger, Katia
Locker, Gershon Y.
Golan, Talia
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
[28] A phase III, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer (GC) that responded to platinum-based first-line chemotherapy.
Ciardiello, Fortunato
Bang, Yung-Jue
Bendell, Johanna C.
Cervantes, Andres
Brachmann, Rainer Karl
Zhang, Yuting
Raponi, Mitch
Farin, Heinrich
Lin, Shen
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[29] Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
Galsky, Matt D.
Pal, Sumanta K.
Mortazavi, Amir
Milowsky, Matthew I.
George, Saby
Gupta, Sumati
Fleming, Mark T.
Dang, Long H.
Geynisman, Daniel M.
Walling, Radhika
Alter, Robert S.
Robin, Erwin L.
Wang, Jue
Gupta, Shilpa
Chism, David D.
Picus, Joel
Philips, George
Quinn, David I.
Hahn, Noah M.
Yu, Menggang
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[30] A phase 3, double-blind, randomized study of pamiparib versus placebo as maintenance therapy in patients with inoperable, locally advanced, or metastatic gastric cancer that responded to platinum-based first-line chemotherapy - Trial in progress
Ciardiello, F.
Bang, Y.
Bendell, J.
Cervantes, A.
Brachmann, R.
Zhang, Y.
Raponi, M.
Farin, H.
Shen, L.
ANNALS OF ONCOLOGY, 2018, 29

← 1 2 3 4 5 →